期刊文献+

加替沙星-聚癸二酸酐局部缓释系统的体内释药特性 被引量:2

Drug release characteristics of gatifloxacin-poly sebacic anhydride local controlled release system
下载PDF
导出
摘要 背景:全身大剂量应用抗生素治疗骨感染的不良反应较多,效果不是十分理想,因此探索一种以可降解材料为载体预防骨感染的方法具有很好的应用价值。目的:分析加替沙星-聚癸二酸酐局部缓释系统的体内释药特性。方法:在新西兰大耳白兔右侧膝关节制作3mm×6mm大小的骨窗,植入加替沙星-聚癸二酸酐缓释制剂,术后1,2,3,6,9,12,15,18,25,30d取心脏血、骨组织及骨髓组织标本,以高效液相色谱法测定各组织内加替沙星浓度;扫描电镜观察加替沙星-聚癸二酸酐缓释制剂植入前后的结构变化。结果与结论:加替沙星-聚癸二酸酐缓释制剂植入后,骨髓组织内药物浓度逐渐降低,在第1天出现了一个较高的高峰,第3-15天药棒释放较平稳,15-30d逐渐降低,但在30d末时的药物浓度仍大于对金黄色葡萄球菌的最小抑菌浓度0.1mg/L;骨组织内的药物浓度高峰出现于第3天,其余时间的浓度较平稳,并且均大于0.1mg/L;在同一时间点,血标本中药物浓度小于骨髓组织和骨组织内药物浓度。加替沙星-聚癸二酸酐缓释制剂是表面溶蚀降解,降解残留物为小球状,其内部结构未发生变化,在药物持续释放过程中药棒未发生崩解和碎片化。表明加替沙星-聚癸二酸酐局部缓释制剂具有良好的载药及药物缓释能力。 BACKGROUND:High-dose antibiotics for bone infection have many adverse reactions, and its outcomes are not perfect. Thus, to explore a degradable material as a vector to prevent bone infection is valuable. OBJECTIVE:To study drug release characteristics of gatifloxa-poly sebacic anhydride local control ed release system in vivo. METHODS:A 3 mm × 6 mm bone window was made at right knee joint of New Zealand rabbits. The gatifloxacin-poly sebacic anhydride sustained release preparation was implanted. Heart blood, bone tissue and myeloid tissue specimens were obtained at 1, 2, 3, 6, 9, 12, 15, 18, 25 and 30 days after surgery. High-performance liquid chromatography was utilized to determine gatifloxacin concentration. Scanning electron microscope was employed to observe the structural changes before and after implantation of gatifloxacin-poly sebacic anhydride sustained release preparation. RESULTS AND CONCLUSION:After implantation of gatifloxacin-poly sebacic anhydride sustained release preparation, drug concentration gradual y decreased in the myeloid tissue, peaked at 1 day, stabilized at 3-15 days, gradual y reduced at 15-30 days. However, the drug concentration was stil higher than the minimal inhibitory concentration 0.1 mg/L against Staphylococcus aureus at 30 days. The peak of drug concentration in the bone tissue occurred at 3 days, and stabilized at other days, which was higher than 0.1 mg/L. At the same time point, drug concentration in the blood specimen was lower than that in the myeloid tissue and bone tissue. The degradation of gatifloxacin-poly sebacic anhydride sustained release preparation was surface erosion, and the shape of the degradation residue is smal globular. The change of the internal structure of gatifloxacin-poly sebacic anhydride sustained release preparation was not found. In the drug release procedure, gatifloxacin-poly sebacic anhydride sustained release preparation did not show disintegration or fragmentation. These results indicated that gatifloxacin-poly sebacic anhydride local sustained release preparation has good abilities of drug load and drug release.
出处 《中国组织工程研究》 CAS CSCD 2013年第29期5351-5356,共6页 Chinese Journal of Tissue Engineering Research
关键词 生物材料 生物材料与药物控释 加替沙星-聚癸二酸酐缓释制剂 骨感染 加替沙星 生物相容性 生物降解 聚酸酐 biomaterials biomaterials and controlled drug release gatifloxacin-poly sebacic anhydride sustained release preparations bone infection gatifloxacin biocompatibility biodegradation poiy anhydride
  • 相关文献

参考文献7

二级参考文献19

  • 1徐勤,邓立东.高效液相色谱法测定犬血清中加替沙星的浓度及其药动学[J].中国医院药学杂志,2004,24(9):539-541. 被引量:4
  • 2[1]Perry-CM,Barman-Balfour-JA,Lamb-HM,et al.Gatifloxacin[J]. Drugs,1999,58(4):683.
  • 3Hosaka M, Yasue T, Fukda H, et al. In vitro and in vivo antibact-aterial activities of AM-155, a new 6 fluoro-8-methoxy quinolone[J]. Antimicrob Agents Chemother, 1992,36(10) :2108-2119.
  • 4Tomioka H, SaitoH, Sayo K. Comparative antiraycobacterial activities of the newly synthesized quinolone AM-1155,sparfloxacin, and ofloxacin[J]. Antimicrob Agents Chemother,1993,37(6) :1257-1259.
  • 5Ednid LM, Jacobs MR, Appelbaum PC. Acitivities of gatifloxacin to those of seven other agents anaerobic organisms[J]. Antimicrob Agents Chemother,1998 42(9) 2459-2461.
  • 6Fukuda H, Hori S, Hiramatsu K. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone- resistent mutants and the nor A transformant of staphylococcus [J]. Antimicrob Agents Chemother, 1998, 42(8) : 1917-1920.
  • 7Miyashita N,Niki Y,Kishimoto T,et al. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia Spp [J]. Antimicrob Agents Chemother, 1997, 41(6) : 1331-1332.
  • 8Lubasch A, Keller I, Borner K,et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers.J Anthmicrob Agents Chemother,2000,44(10) :2600
  • 9Naber CK, Steghafner M, Kingig-Schippers M, et al. Concentrations of gatifloxacin mesylate in plasma and urine and penetrition into prostatic and seminal fluid,ejaculate,and sperm cells after single oral administrations of 400 milligrams to volunteers. J Anthmicrob Agents Chemother,2001,45 (1) :293
  • 10Nakashima M, Uematsu T, Kosuge K,et al. Single - and multiple -dose pharmacokinetics of AM - 1155, a new 6 - fluoro - 8 - methoxy quinolone, in humans. J Antimicrob Agents Chemother, 1995, 39(12) :2635

共引文献34

同被引文献28

  • 1李绪春,朱红.单剂量加替沙星口服在Beagle犬体内药代动力学研究[J].中国药业,2006,15(10):6-7. 被引量:4
  • 2吴瀛达,戚双双.加替沙星不良反应23例分析[J].中国药物与临床,2006,6(10):799-800. 被引量:12
  • 3杨秀芬,曾繁典,周志彬,黄开勋,徐辉碧.聚(油酸/亚油酸-癸二酸)-庆大霉素在家兔体内的释药实验及相容性研究[J].中国新药杂志,2007,16(16):1265-1268. 被引量:1
  • 4Domb AJ,Rock M,Perkin C.Excretion of a radiolabeledanticancer biodegradable polymeric implant from the rabbitbrain.Biomaterials.1995;16(14):1069-1072.
  • 5Norden CW,Shafferm M.Experimental osteomyelitis due toStaphylococcus aureus or Pseudomonas aeruginosa:aradiographic-pathological correlative analysis.Br J Exp Pathol.1980;61(4):451-460.
  • 6Laurence ED,Charle H.Gentamicin-loaded plaster of Parisas a treatment of experimental osteomyelitis in rabbits.ClinOrthop Relat Res.1987:(219):278-282.
  • 7Ostermann PA,Seiigson D,Henry SL.Local antibiotic therapyfor severe open fractures.A review of 1085 consecutivecases.J Bone Joint Surg Br.1995:77(1):93-97.
  • 8Grace EJ,Bryoson V.Modern treatment of chronicosteomyelitis with topical detergent antibiotic therapy.SurgGynecol Obstet.1950;91(3):333-342.
  • 9Perry CR,Kitterbusch JK,Rice SH,et al.Antibiotics deliveredby an implantable drug pump;a new application for treatingosteomyelitis.Am J Med.1986;80(6B):222-227.
  • 10Kahn DS,Pritzker KP.The pathophysiology of bone infection.Clin Orthop Relat Res.1973;8(96):12-19.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部